Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Last Name

profileAshujit Tagde, Ph.D.

TitleResearch Fellow in Medicine (EXT)
InstitutionDana-Farber Cancer Institute
AddressDana-Farber Cancer Institute
44 Binney St
Boston MA 02115
vCardDownload vCard (login for email)

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Maeda T, Hiraki M, Jin C, Rajabi H, Tagde A, Alam M, Bouillez A, Hu X, Suzuki Y, Miyo M, Hata T, Hinohara K, Kufe D. MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer. Cancer Res. 2018 Jan 01; 78(1):205-215. PMID: 29263152.
    View in: PubMed
  2. Tagde A, Markert T, Rajabi H, Hiraki M, Alam M, Bouillez A, Avigan D, Anderson K, Kufe D. Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma. Oncotarget. 2017 Sep 19; 8(41):69237-69249. PMID: 29050200.
    View in: PubMed
  3. Rajabi H, Hiraki M, Tagde A, Alam M, Bouillez A, Christensen CL, Samur M, Wong KK, Kufe D. MUC1-C activates EZH2 expression and function in human cancer cells. Sci Rep. 2017 Aug 07; 7(1):7481. PMID: 28785086.
    View in: PubMed
  4. Bouillez A, Adeegbe D, Jin C, Hu X, Tagde A, Alam M, Rajabi H, Wong KK, Kufe D. MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. Oncoimmunology. 2017; 6(9):e1338998. PMID: 28932637.
    View in: PubMed
  5. Yin L, Tagde A, Gali R, Tai YT, Hideshima T, Anderson K, Avigan D, Kufe D. MUC1-C is a target in lenalidomide resistant multiple myeloma. Br J Haematol. 2017 09; 178(6):914-926. PMID: 28643330.
    View in: PubMed
  6. Pyzer AR, Stroopinsky D, Rosenblatt J, Anastasiadou E, Rajabi H, Washington A, Tagde A, Chu JH, Coll M, Jiao AL, Tsai LT, Tenen DE, Cole L, Palmer K, Ephraim A, Leaf RK, Nahas M, Apel A, Bar-Natan M, Jain S, McMasters M, Mendez L, Arnason J, Raby BA, Slack F, Kufe D, Avigan D. MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia. 2017 Dec; 31(12):2780-2790. PMID: 28555079.
    View in: PubMed
  7. Bouillez A, Rajabi H, Jin C, Samur M, Tagde A, Alam M, Hiraki M, Maeda T, Hu X, Adeegbe D, Kharbanda S, Wong KK, Kufe D. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene. 2017 Jul 13; 36(28):4037-4046. PMID: 28288138.
    View in: PubMed
  8. Pyzer AR, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, Fung J, Bryant MP, Cole L, Palmer K, Somaiya P, Karp Leaf R, Nahas M, Apel A, Jain S, McMasters M, Mendez L, Levine J, Joyce R, Arnason J, Pandolfi PP, Kufe D, Rosenblatt J, Avigan D. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017 Mar 30; 129(13):1791-1801. PMID: 28126925.
    View in: PubMed
  9. Rajabi H, Tagde A, Kufe D. MUC1-C drives DNA methylation in cancer. Aging (Albany NY). 2016 12 28; 8(12):3155-3156. PMID: 28039441.
    View in: PubMed
  10. Hiraki M, Maeda T, Bouillez A, Alam M, Tagde A, Hinohara K, Suzuki Y, Markert T, Miyo M, Komura K, Ahmad R, Rajabi H, Kufe D. MUC1-C activates BMI1 in human cancer cells. Oncogene. 2017 May 18; 36(20):2791-2801. PMID: 27893710.
    View in: PubMed
  11. Alam M, Bouillez A, Tagde A, Ahmad R, Rajabi H, Maeda T, Hiraki M, Suzuki Y, Kufe D. MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway. Mol Cancer Res. 2016 Dec; 14(12):1266-1276. PMID: 27658423.
    View in: PubMed
  12. Tagde A, Rajabi H, Stroopinsky D, Gali R, Alam M, Bouillez A, Kharbanda S, Stone R, Avigan D, Kufe D. MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. Oncotarget. 2016 Jun 28; 7(26):38974-38987. PMID: 27259275.
    View in: PubMed
  13. Rajabi H, Tagde A, Alam M, Bouillez A, Pitroda S, Suzuki Y, Kufe D. DNA methylation by DNMT1 and DNMT3b methyltransferases is driven by the MUC1-C oncoprotein in human carcinoma cells. Oncogene. 2016 Dec 15; 35(50):6439-6445. PMID: 27212035.
    View in: PubMed
  14. Hasegawa M, Takahashi H, Rajabi H, Alam M, Suzuki Y, Yin L, Tagde A, Maeda T, Hiraki M, Sukhatme VP, Kufe D. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. Oncotarget. 2016 Mar 15; 7(11):11756-69. PMID: 26930718; PMCID: PMC4914246.
  15. Tagde A, Rajabi H, Bouillez A, Alam M, Gali R, Bailey S, Tai YT, Hideshima T, Anderson K, Avigan D, Kufe D. MUC1-C drives MYC in multiple myeloma. Blood. 2016 05 26; 127(21):2587-97. PMID: 26907633; PMCID: PMC4882805 [Available on 05/26/17].
  16. Bouillez A, Rajabi H, Pitroda S, Jin C, Alam M, Kharbanda A, Tagde A, Wong KK, Kufe D. Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas. Cancer Res. 2016 Mar 15; 76(6):1538-48. PMID: 26833129; PMCID: PMC4794417 [Available on 03/15/17].
  17. Takahashi H, Jin C, Rajabi H, Pitroda S, Alam M, Ahmad R, Raina D, Hasegawa M, Suzuki Y, Tagde A, Bronson RT, Weichselbaum R, Kufe D. MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Oncogene. 2015 Oct 01; 34(40):5187-97. PMID: 25659581; PMCID: PMC4530107.
  18. Sonawane P, Cho HE, Tagde A, Verlekar D, Yu AL, Reynolds CP, Kang MH. Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma. Br J Pharmacol. 2014 Dec; 171(23):5330-44. PMID: 25039756; PMCID: PMC4294043.
  19. Tagde A, Singh H, Kang MH, Reynolds CP. The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma. Blood Cancer J. 2014 Jul 18; 4:e229. PMID: 25036800; PMCID: PMC4219442.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at For faculty personal and demographic information, contact HMS Office for Faculty Affairs at
Tagde's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
Co-Authors Expand Description
Similar People Expand Description
Same Department Expand Description